Company registration number 08849265 (England and Wales)
CLINICAL INNOVATIONS EUROPE LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
CLINICAL INNOVATIONS EUROPE LIMITED
COMPANY INFORMATION
DIRECTORS
Michael Frazzette
Holger Furstenberg
Paul Haydock
COMPANY NUMBER
08849265
REGISTERED OFFICE
7 The I.O. Centre
Jugglers Close
Banbury
OX16 3TA
ACCOUNTANTS
Kilsby & Williams LLP
Cedar House
Hazell Drive
Newport
Gwent
NP10 8FY
CLINICAL INNOVATIONS EUROPE LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 3
CLINICAL INNOVATIONS EUROPE LIMITED
BALANCE SHEET
AS AT
31 MARCH 2024
31 March 2024
- 1 -
2024
2023
Notes
$
$
CURRENT ASSETS
-
-
Debtors
3
10,074,549
10,074,549
NET CURRENT ASSETS
10,074,549
10,074,549
CAPITAL AND RESERVES
Called up share capital
1
1
Other reserves
1,014,132
1,014,132
Profit and loss reserves
9,060,416
9,060,416
TOTAL EQUITY
10,074,549
10,074,549
The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true
For the financial year ended 31 March 2024 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The financial statements were approved by the board of directors and authorised for issue on 8 October 2024 and are signed on its behalf by:
Holger Furstenberg
Director
Company registration number 08849265 (England and Wales)
CLINICAL INNOVATIONS EUROPE LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
- 2 -
1
ACCOUNTING POLICIES
Company information
Clinical Innovations Europe Limited is a private company limited by shares incorporated in England and Wales. The registered office is 7 The I.O. Centre, Jugglers Close, Banbury, OX16 3TA.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in US dollars, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest $.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
1.2
Going concern
On 1 April 2022, the company transferred its trade, assets, liabilities and employees to the UK branch of Medical Measurement System B.V., a company headquartered in The Netherlands. As a result, the accounts have been prepared on a break up basis.true
1.3
Profit and loss account
The company has not traded during the year. During this time, the company received no income and incurred no expenditure and therefore no Profit and loss account is presented in these financial statements.
1.4
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
1.5
Foreign exchange
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.
CLINICAL INNOVATIONS EUROPE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024
- 3 -
2
EMPLOYEES
The average monthly number of persons (including directors) employed by the company during the year was:
2024
2023
Number
Number
Total
3
DEBTORS
2024
2023
Amounts falling due within one year:
$
$
Amounts owed by group undertakings
10,074,549
10,074,549
4
PARENT COMPANY
At the balance sheet date the immediate parent undertaking was Clinical Innovations LLC, registered in USA.
The ultimate controlling party was Laborie Medical Technologies Corp., registered in USA.